Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$48.92 USD

48.92
781,658

+0.63 (1.30%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $48.99 +0.07 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus

by Zacks Equity Research

We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.

Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?

by Zacks Equity Research

In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.

Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies

by Zacks Equity Research

Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.

Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $64.40, moving +1.31% from the previous trading session.

Vertex (VRTX) to Begin Pivotal Study on Kidney Candidate

by Zacks Equity Research

Vertex's (VRTX) pivotal phase III study on VX-147 targeting a broad patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD) is expected to begin later this month.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $67.89 in the latest trading session, marking a +0.64% move from the prior day.

CRISPR Therapeutics AG (CRSP) Up 5.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Intellia (NTLA) Depreciates 27% Over a Month: Here's Why

by Zacks Equity Research

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $62.43, marking a +0.02% move from the previous day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving -1.85% from the previous trading session.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $62.36 in the latest trading session, marking a +0.76% move from the prior day.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59, marking a +0.41% move from the previous day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $61.84, moving -1.12% from the previous trading session.

4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

by Zacks Equity Research

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

by Zacks Equity Research

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $67.66 in the latest trading session, marking a +0.71% move from the prior day.

Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition

by Zacks Equity Research

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Ekta Bagri headshot

4 Biotechs That Could Be Potential Takeover Targets in 2022

by Ekta Bagri

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $82.15, marking a +0.72% move from the previous day.